Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Annovis Bio Inc
(NY:
ANVS
)
7.290
+0.210 (+2.97%)
Official Closing Price
Updated: 7:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Annovis Bio Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
August 18, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
August 18, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
ANVS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Annovis Bio, Inc.
August 17, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
August 05, 2021
From
Law Offices of Howard G. Smith
Via
Business Wire
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm
August 03, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
August 03, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
August 03, 2021
From
The Law Offices of Frank R. Cruz
Via
Business Wire
61 Biggest Movers From Yesterday
August 03, 2021
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....
Via
Benzinga
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.
August 02, 2021
From
Kirby McInerney LLP
Via
Business Wire
40 Stocks Moving In Monday's Mid-Day Session
August 02, 2021
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:...
Via
Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
July 29, 2021
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Via
The Motley Fool
63 Biggest Movers From Friday
August 02, 2021
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the...
Via
Benzinga
Exposures
Product Safety
ANVS Stock: The Alzheimer’s Drug News That Has Annovis Bio Plunging Today
July 29, 2021
Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug.
Via
InvestorPlace
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
70 Biggest Movers From Yesterday
July 30, 2021
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private...
Via
Benzinga
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
July 29, 2021
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases...
Via
Benzinga
Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet
July 29, 2021
Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, gaining 0.61% to 4,427.36. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
44 Stocks Moving In Thursday's Mid-Day Session
July 29, 2021
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia....
Via
Benzinga
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
July 29, 2021
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
July 29, 2021
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
Via
Investor's Business Daily
28 Stocks Moving in Thursday's Pre-Market Session
July 29, 2021
Gainers LendingClub Corporation (NYSE: LC) shares rose 44.6% to $23.49 in pre-market trading after the company reported better-than-expected Q2 results and raised guidance. Acer...
Via
Benzinga
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
July 23, 2021
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.
Via
Investor's Business Daily
Annovis Bio's Alzheimer's Candidate To Proceed Into Final Cohort Of Mid-Stage Study, Data Expected In 2022
July 20, 2021
Data Safety Monitoring Board (DSMB) has reviewed safety and tolerability data for Cohort 2 of Annovis Bio Inc's (NYSE: ANVS) Phase 2 Alzheimer's disease trial...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks
July 17, 2021
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.
Via
The Motley Fool
Here's Why The Biotech Stocks You Bought Keep Going Down
July 17, 2021
Good news! There's a way to avoid this portfolio pain -- and it doesn't involve avoiding the whole sector.
Via
The Motley Fool
Better Biotech Stock: Biogen vs. Annovis Bio
July 16, 2021
Both are making Alzheimer's drugs, but only one can claim success as of today.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.